Increasing options for the treatment of osteoporosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

33 citing papers in PubMed.

1. Five-year follow-up study of a kidney-tonifying herbal Fufang for prevention of postmenopausal osteoporosis and fragility fractures.Journal of bone and mineral metabolism · 2012
   Trial
2. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2012
   Trial
3. Pharmacological mechanism of natural products to treat osteoporosis: a focus on the autophagy.Frontiers in pharmacology · 2025
   Review
4. Synthetic biology-based bacterial extracellular vesicles displaying BMP-2 and CXCR4 to ameliorate osteoporosis.Journal of extracellular vesicles · 2024
   Article
5. Resorbable GBR Scaffolds in Oral and Maxillofacial Tissue Engineering: Design, Fabrication, and Applications.Journal of clinical medicine · 2023
   Review
6. Molecules (Basel, Switzerland) · 2020
   Article
7. Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis.Scientific reports · 2020
   Observational
8. 2-NPPA Mitigates Osteoclastogenesis via Reducing TRAF6-Mediated c-fos Expression.Frontiers in pharmacology · 2020
   Article
9. Costunolide-A Bioactive Sesquiterpene Lactone with Diverse Therapeutic Potential.International journal of molecular sciences · 2019
   Review
10. Bone marrow mesenchymal stem cells: Aging and tissue engineering applications to enhance bone healing.Biomaterials · 2019
    Review
11. Inhibitory Effects of 2N1HIA (2-(3-(2-Fluoro-4-Methoxyphenyl)-6-Oxo-1(6H)-Pyridazinyl)-Molecules (Basel, Switzerland) · 2018
    Article
12. The Effect of Inhalant Organic Dust on Bone Health.Current allergy and asthma reports · 2018
    Review
13. Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned.Endocrine reviews · 2017
    Review
14. Evaluation of Osteogenesis and Angiogenesis of Icariin in Local Controlled Release and Systemic Delivery for Calvarial Defect in Ovariectomized Rats.Scientific reports · 2017
    Article
15. Can denosumab be a substitute, competitor, or complement to bisphosphonates?The Korean journal of pain · 2017
    Review
16. Safety and efficacy of denosumab in osteoporotic hemodialysed patients.Journal of nephrology · 2017
    Observational
17. Bisphosphonates and atypical subtrochanteric fractures of the femur.Bone & joint research · 2017
    Article
18. Intravenous zoledronate for osteoporosis: less might be more.Therapeutic advances in musculoskeletal disease · 2016
    Review
19. [Novel anti-osteoporotic drugs on the horizon].Zeitschrift fur Rheumatologie · 2016
    Review
20. Increased Bone Mass in Female Mice Lacking Mast Cell Chymase.PloS one · 2016
    Article

Corrections and comments

• Comment on
  Denosumab for prevention of fractures in postmenopausal women with osteoporosis.2009
• Comment on
  Denosumab in men receiving androgen-deprivation therapy for prostate cancer.2009

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as